B Cell Epitopes of Four Fimbriae Antigens of Klebsiella pneumoniae : A Comprehensive In Silico Study for Vaccine Develop
- PDF / 3,082,209 Bytes
- 12 Pages / 595.276 x 790.866 pts Page_size
- 71 Downloads / 154 Views
B Cell Epitopes of Four Fimbriae Antigens of Klebsiella pneumoniae: A Comprehensive In Silico Study for Vaccine Development Fatemeh Nemati Zargaran1 · Alisha Akya1 · Shahab Rezaeian1 · Keyghobad Ghadiri1 · Roya Chegene Lorestani1 · Hamid Madanchi2,3 · Sadegh Safaei4,5 · Mosayeb Rostamian1 Accepted: 28 October 2020 © Springer Nature B.V. 2020
Abstract Klebsiella pneumoniae is one of the major causes of nosocomial infections worldwide which can cause several diseases in children and adults. The globally dissemination of hyper-virulent strains of K. pneumoniae and the emergence of antibioticsresistant isolates of this pathogen narrows down the treatment options and has renewed interest in its vaccines. Vaccine candidates of Klebsiella pneumoniae have not been adequately protective, safe and globally available yet. In K. pneumoniae infection, it is well known that B cells that induce robust humoral immunity are necessary for the host complete protection. Identifying the B cell epitopes of antigens is valuable to design novel vaccine candidates. In the present study using immunoinformatics approaches we found B cell epitopes of four K. pneumoniae type 1 fimbriae antigens namely FimA, FimF, FimG, and FimH. Linear and conformational B cell epitopes of each antigen were predicted using different programs. Subsequently, many bioinformatics assays were applied to choose the best epitopes including prediction antigenicity, toxicity, human similarity and investigation on experimental records. These assays resulted in final four epitopes (each for one Fim protein). These final epitopes were modeled and their physiochemical properties were estimated to be used as potential vaccine candidates. Altogether, we found four B cell epitopes of K. pneumoniae Fim antigens that are immunogen, antigenic, not similar to human peptides, not allergen and not toxic. Also, they have suitable physiochemical properties to administrate as vaccine, although their complete efficacy should be also shown in vitro and in vivo. Keywords Klebsiella pneumoniae · Vaccine · Immunoinformatics · B cell epitopes
Introduction Electronic supplementary material The online version of this article (https://doi.org/10.1007/s10989-020-10134-3) contains supplementary material, which is available to authorized users. * Mosayeb Rostamian [email protected] 1
Infectious Diseases Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran
2
Department of Biotechnology, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran
3
Drug Design and Bioinformatics Unit, Department of Medical Biotechnology, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
4
Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran
5
Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran
Klebsiella pneumoniae is one of the major causes of nosocomial infections worldwide (Podschun and Ullma
Data Loading...
